Leading Companies Fueling Growth and Innovation in the Anti-Rabies Serum Market

A growing global concern about rabies and the need for effective prevention measures have positioned the anti-rabies serum market for significant expansion. As healthcare systems strengthen and awareness rises, this sector is expected to witness steady growth, driven by innovations and strategic collaborations. Let's explore the key market outlook, major players, emerging trends, and detailed segment analysis shaping the future of the anti-rabies serum industry.

Forecasted Valuation and Growth Trajectory of the Anti-Rabies Serum Market
The anti-rabies serum market is projected to achieve substantial growth, reaching a valuation of $1.95 billion by 2030. This growth reflects a compound annual growth rate (CAGR) of 5.3% during the forecast period. Several factors contribute to this expansion, including increased use of human anti-rabies immunoglobulin, broader rabies prevention programs in developing countries, greater investments in biologics manufacturing, a rising emphasis on safer serum alternatives, and the strengthening of public health vaccination systems. Key trends expected to influence the market include a shift toward human-derived immunoglobulins, a growing preference for prefilled syringe formats, development of cold-chain optimized serum distribution methods, enhanced focus on high-purity antibody formulations, and improved standardization of protocols for post-exposure prophylaxis.

Download a free sample of the anti-rabies serum market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20468&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving the Anti-Rabies Serum Market
Major players currently shaping the anti-rabies serum landscape include Merck & Co Inc., Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, HCX Pharmaceuticals LLP, Intas Pharmaceuticals Ltd, Bavarian Nordic AS, Serum Institute of India Pvt Ltd., Bharat Serums And Vaccines Limited, Indian Immunologicals Ltd., Bharat Biotech, National Institute of Health Islamabad, ViNS Bioproducts Ltd., Shanghai Serum Bio-technology, Premium Serums and Vaccines Pvt Ltd., Congruent Pharmachem, Haffkine Bio Pharmaceutical Corporation Limited, LEXICARE PHARMA PVT. LTD., Avin Darou, Central Research Institute Kasauli, and Vigilomed Pharmaceuticals.

Recent Strategic Partnership Enhancing Market Reach
In December 2023, Kedrion Biopharma, an Italy-based biopharmaceutical firm specializing in plasma-derived therapeutics, signed a binding memorandum of understanding with Kamada Ltd to deepen their collaboration around the human rabies immune globulin product KEDRAB. This partnership aims to secure a long-term supply of KEDRAB, expand commercial distribution channels, and boost market opportunities in rabies prevention. Kamada Ltd., headquartered in Israel, focuses on plasma-derived protein therapeutics, making this alliance a strategic move to strengthen their combined position in the anti-rabies serum market.

View the full anti-rabies serum market report:
https://www.thebusinessresearchcompany.com/report/anti-rabies-serum-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

How Strategic Collaborations Will Influence the Anti-Rabies Serum Market
Leading companies in the anti-rabies serum sector are increasingly leveraging strategic partnerships to accelerate product innovation and broaden their market footprint. These collaborations allow firms to share resources and expertise, fostering mutual growth and enhanced capabilities. For example, in July 2023, Kedrion S.p.A. from the U.S. partnered with Kamada, the Israeli biopharmaceutical company, to co-develop and distribute KEDRAB (Rabies Immune Globulin [Human]) in the U.S. This partnership has played a vital role in licensing the product domestically and raising public awareness about rabies, ultimately contributing to better protection against this potentially fatal disease among people exposed to rabid animal bites.

Detailed Segment Breakdown of the Anti-Rabies Serum Market
The report segments the anti-rabies serum market into several categories for a comprehensive understanding:
1) By Type: Human Anti-rabies Immunoglobulin and Equine Anti-rabies Immunoglobulin
2) By Dosage and Form: Vials and Prefilled Syringes
3) By Route of Administration: Intravenous and Intramuscular
4) By End User: Hospitals, Clinics, and Veterinary Hospitals

Further subcategories include:
- For Human Anti-Rabies Immunoglobulin: Monovalent, Polyvalent, Intramuscular, Intravenous, and Freeze-Dried forms
- For Equine Anti-Rabies Immunoglobulin: Freeze-Dried, Liquid, Monovalent, and Polyvalent formulations

This segmentation offers a nuanced view of the market, highlighting product variations and usage patterns critical to stakeholders and healthcare providers.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.